Skip to main content

Cenix, AstraZeneca Team on Gene Silencing Oncology Rx Studies

NEW YORK (GenomeWeb News) – Cenix BioScience said today it will work with the drug developer AstraZeneca in a tailored RNAi research collaboration aimed at advancing oncology drug targets.
 
Under the agreement, Cenix will combine its RNAi-based gene silencing technology with phenotypic analyses in cultured human cells. The research program will initially involve a high-throughput RNAi screen using an assay that the companies will design together to find and validate novel targets for cancer treatments.
 
Cenix said it would implement multi-parametric microscopy-based assays using Definiens’ Cellenger image analysis platform to provide datasets of cellular functions and the phenotypes of certain genes. These data can be used to discover and prioritize targets for drug development, Dresden, Germany-based Cenix said.
 
“We look forward to driving this relationship beyond the initial pilot through to multiple projects,” Cenix CEO and CSO Christophe Echeverri said in a statement.
 

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.